Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8284394 | 0.88 | KCNH2 (0.42) | ALDH1A1MEN1KMT2ATRPC5LMNA | |
| SCHEMBL4856917 | 0.87 | SSTR5 (0.41) | SOS1MEN1KMT2ATRPC5LMNA | |
| SCHEMBL4858155 | 0.83 | HDAC1 (0.35) | SOS1TRPC5KCNH2NR4A2DHFR | |
| SCHEMBL4858151 | 0.83 | HDAC1 (0.35) | SOS1TRPC5KCNH2NR4A2DHFR | |
| SCHEMBL4864355 | 0.82 | TRPC5 (0.44) | ALDH1A1MEN1KMT2ATRPC5LMNA | |
| SCHEMBL1238593 | 0.81 | KCNH2 (0.43) | MEN1KMT2ALMNAEGFRKCNH2 | |
| SCHEMBL14002729 | 0.81 | TRPC5 (0.42) | ALDH1A1MEN1KMT2ATRPC5LMNA | |
| SCHEMBL8294761 | 0.80 | KCNH2 (0.42) | MEN1KMT2ALMNAEGFRKCNH2 | |
| SCHEMBL1237484 | 0.79 | KCNH2 (0.41) | MEN1KMT2ALMNAEGFRKCNH2 | |
| SCHEMBL8293191 | 0.78 | KCNH2 (0.40) | ALDH1A1MEN1KMT2ALMNAEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883837-B2 | Morpholinyl containing benzimidazoles as inhibitors of respiratory syncytial virus replication | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-11 | — | — | US | disclosed |
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | JANSSEN SCIENCES IRELAND UC (IE) | 2008-11-13 | — | — | US | disclosed |
| US-7449463-B2 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-11-11 | — | — | US | disclosed |
| EP-1697345-B1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | TIBOTEC PHARM LTD (IE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | JANSSEN SCIENCES IRELAND UC (IE) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280881-A1 | MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION | RIN1, ZC3HAV1L, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SOS1 1526/4885ALDH1A1 3486/4885MEN1 2761/4885 |
| US-20070043022-A1 | 2-[6-{[2-(3-Hydroxy-propyl)-5-methyl-phenylamino]-methyl}-2-(3-morpholin-4-yl-propylamino)-benzimidazol-1-ylmethyl]-6-methyl-pyridin-3-ol, or its N-oxide, salt, quaternary amine, or metal complex; optionally with an additional antiviral agent | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-3 | SOS1 2969/4885ALDH1A1 3915/4885MEN1 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.